Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer

Norihiro Yamaguchi(Harvard University), Daniel B. Costa(Beth Israel Deaconess Medical Center)

Lung Cancer

October 14, 2013

10.1016/j.lungcan.2013.09.019

Cited by 93

Related Papers

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

|Journal of Clinical Oncology|2011|590

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

|PLoS Medicine|2007|490

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

|JTO Clinical and Research Reports|2020|81

EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors

|Lung Cancer|2023|6